CRISPR gene editing firm Editas Medicine (EDIT) signed a collaboration agreement with a small cap gene therapy firm called Adverum Biotechnologies (ADVM). The collaboration aims at exploring the delivery of Editas’ genome editing approach with Adverum’s next-generation adeno-associated viral (AAV) vectors to treat up to five inherited retinal diseases that have yet to find treatments or have poor existing remedies.
According to the agreement, Editas is to pay Adverum $1 million up front to evaluate its vectors for use in clinical development. It . . .